Treatment of newly diagnosed multiple myeloma: advances in current therapy
- PMID: 20035387
- DOI: 10.1007/s12032-009-9370-1
Treatment of newly diagnosed multiple myeloma: advances in current therapy
Abstract
The past decade has seen incredible progress in the treatment of myeloma as a result of more widespread application of autologous stem cell transplantation and introduction of several new drugs. Hence, the survival of patients with this disease has significantly improved during this period. The treatment approach for patients with myeloma has undergone a paradigm shift as a result of the different choices available for treating the patients with newly diagnosed myeloma. In addition, appreciation of the heterogeneity in the outcome of these patients and the impact of genetics on the prognosis has led to efforts at developing a risk-adapted approach to treatment. This article summarizes the recent advances in the treatment of newly diagnosed myeloma and suggests a treatment algorithm for approaching newly diagnosed myeloma.
Similar articles
-
Treatment of multiple myeloma.Nat Rev Clin Oncol. 2011 Apr 26;8(8):479-91. doi: 10.1038/nrclinonc.2011.63. Nat Rev Clin Oncol. 2011. PMID: 21522124 Free PMC article. Review.
-
Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.Curr Hematol Malig Rep. 2021 Apr;16(2):148-161. doi: 10.1007/s11899-021-00631-7. Epub 2021 Apr 19. Curr Hematol Malig Rep. 2021. PMID: 33876390 Review.
-
Clinical treatment of newly diagnosed multiple myeloma.Expert Rev Hematol. 2015 Oct;8(5):595-611. doi: 10.1586/17474086.2015.1078236. Epub 2015 Sep 1. Expert Rev Hematol. 2015. PMID: 26327587 Review.
-
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.Acta Haematol. 2017;137(3):163-172. doi: 10.1159/000463534. Epub 2017 Apr 12. Acta Haematol. 2017. PMID: 28399522
-
Frontline therapy of multiple myeloma.Blood. 2015 May 14;125(20):3076-84. doi: 10.1182/blood-2014-09-568915. Epub 2015 Apr 2. Blood. 2015. PMID: 25838345 Review.
Cited by
-
Referrals for suspected hematologic malignancy: a survey of primary care physicians.Am J Hematol. 2012 Jun;87(6):634-6. doi: 10.1002/ajh.23172. Epub 2012 Mar 31. Am J Hematol. 2012. PMID: 22473854 Free PMC article.
-
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.Blood. 2015 Jan 15;125(3):443-8. doi: 10.1182/blood-2014-05-573741. Epub 2014 Nov 13. Blood. 2015. PMID: 25395429 Free PMC article. Clinical Trial.
-
CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation.Aging (Albany NY). 2022 Nov 28;14(22):9264-9279. doi: 10.18632/aging.204405. Epub 2022 Nov 28. Aging (Albany NY). 2022. PMID: 36445333 Free PMC article.
-
BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.Med Oncol. 2015 Mar;32(3):81. doi: 10.1007/s12032-015-0542-x. Epub 2015 Feb 20. Med Oncol. 2015. PMID: 25698537
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous